TuHURA Biosciences, Inc.

NASDAQ:HURA

Biotechnology

Healthcare
$1.36 +6.37%

+$0.14 today

Market cap
$89.43M
Beta
0.01
P/E (TTM)
-4.6
EPS (TTM)
-$0.52
52W Low $0.41High $3.90

Volume 0.20M

Average 0.85M

Returns on capital

TuHURA Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-143.6%

avg -145.3%

ROIC

-145.7%

avg 1476.3%

ROA

-109.9%

avg -186.5%

Analysis

ROA is currently the strongest return metric at -109.9% versus its period average of -186.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

James A. Bianco

President, Chief Executive Officer & DirectorUSD 1.12M692.17M3.41%

Dan Dearborn

Executive Vice President of Finance & Chief Financial OfficerUSD 544.04K59273.70K0.43%

Michael Krsulich

Head of Quality Assurance————

Michael Lawman

Co-Founder————

Patricia Lawman

Co-Founder————

Amanda Garofalo

Senior Vice President of Clinical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 28, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does TuHURA Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about HURA's management, answered from reported figures.

Who manages HURA?

TuHURA Biosciences, Inc. (HURA) lists 6 active executives. The top listed executive is Dan Dearborn, Executive Vice President of Finance & Chief Financial Officer.

Are HURA insiders buying or selling?

Recent insider activity shows net buying of $15.55M.